Ignite Creation Date:
2024-07-17 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481345
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-25
Brief Title:
Characterization of Myeloproliferative Neoplasia With a Mutated IDH SRSF2 or SF3B1 Allele CARPEDIEM
Sponsor:
University Hospital Brest
Organization:
University Hospital Brest
Study Overview
Official Title:
Characterization of Myeloproliferative Neoplasia With a Mutated IDH SRSF2 or SF3B1 Allele
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CARPEDIEM
Brief Summary:
Retrospective study assessing the impact of IDH12 SRSF2 or SF3B1 mutations on event free survival of MPN patients
Detailed Description:
Patients with a diagnosis of MPN and a mutation of IDH12 SRSF2 or SF3B1 will be included Clinical and biological characterisation at diagnosis as well as evlution will be recorded Event free survival will be assessed in each group event thrombosis transformation to mylofibrosisacute leukemia death
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None